Femasys (NASDAQ:FEMY) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Femasys (NASDAQ:FEMY) from a sell rating to a strong sell rating in a research report released on Saturday,Wall Street Zen reports.

FEMY has been the subject of several other reports. Maxim Group reduced their price objective on Femasys to $10.00 and set a “buy” rating for the company in a report on Friday, August 14th. Lake Street Capital lowered their target price on Femasys to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, August 18th. Finally, Weiss Ratings cut Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Femasys presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Femasys Stock Performance

Shares of FEMY stock opened at $2.02 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.55 and a current ratio of 2.14. The firm has a market cap of $16.93 million, a price-to-earnings ratio of -0.57 and a beta of -2.16. Femasys has a 52 week low of $1.96 and a 52 week high of $22.20. The firm’s 50-day simple moving average is $2.67 and its two-hundred day simple moving average is $5.22.

Femasys (NASDAQ:FEMY) last released its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative net margin of 534.36% and a negative return on equity of 225.97%. The company had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.73 million.

Insider Buying and Selling

In other Femasys news, CFO Dov Elefant purchased 15,625 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, for a total transaction of $50,000.00. Following the purchase, the chief financial officer owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $3.20 per share, with a total value of $50,000.00. Following the completion of the acquisition, the chief executive officer owned 15,625 shares in the company, valued at $50,000. This trade represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 38,750 shares of company stock worth $124,000 over the last 90 days. 7.75% of the stock is currently owned by corporate insiders.

Femasys Company Profile

Femasys Inc is a women’s health company focused on developing and commercializing minimally invasive technologies for reproductive health and fertility care. The company’s products are designed to provide non-surgical or less invasive alternatives for contraception, diagnostic procedures and treatments involving the female reproductive system.

Femasys’ lead product candidate is FemBloc, an investigational, non-surgical permanent birth-control system intended to prevent pregnancy by blocking the fallopian tubes.